2. Search Result
Search Result
Results for "

7-Aminoheptanoic acid

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

4

Peptides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W002042
    7-Aminoheptanoic acid

    		Cancer
    7-Aminoheptanoic acid is a PROTAC linker. 7-Aminoheptanoic acid can be used to synthesize PROTAC molecules (e.g. HL-8 (HY-143275)).
    7-Aminoheptanoic acid
  • HY-W012001
    N-Boc-7-aminoheptanoic acid

    		PROTAC Linkers Cancer
    Boc-7-Aminoheptanoic acid can be used as a PROTAC linker in the synthesis of PROTACs and other conjugation applications. Boc-7-Aminoheptanoic acid is an alkane chain with terminal carboxlic acid and Boc-protected amino groups. The terminal carboxylic acid can react with primary amine groups in the presence of activators (e.g. EDC, or HATU) to form a stable amide bond. The Boc group can be deprotected under mild acidic conditions to form the free amine.
    N-Boc-7-aminoheptanoic acid
  • HY-W160298
    N-Cbz-7-Aminoheptanoic acid

    		Biochemical Assay Reagents Others
    N-Cbz-7-Aminoheptanoic acid is a six carbon linker containing an carboxylic acid (CO2H) group and a benzyl (Cbz) protecting group. The terminal carboxylic acid is reactive with primary amine groups in the presence of activators (e.g. EDC, or HATU) forming a stable amide bond. The benzyl protecting group can be removed via hydrogenolysis to form a free amine.
    N-Cbz-7-Aminoheptanoic acid
  • HY-W009056
    Fmoc-7-amino-heptanoic acid

    		PROTAC Linkers Cancer
    Fmoc-7-amino-heptanoic acid is an alkane chain with terminal Fmoc-protected amine and carboxylic acid groups. Fmoc-7-amino-heptanoic acid can be used as a PROTAC linker in the synthesis of PROTACs. The Fmoc group can be deprotected under basic condition to obtain the free amine which can be used for further conjugations. The terminal carboxylic acid can react with primary amine groups in the presence of activators (e.g. EDC, or HATU) to form a stable amide bond.
    Fmoc-7-amino-heptanoic acid
  • HY-P4146
    Survodutide

    BI 456906

    		 GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide
  • HY-P4146A
    Survodutide TFA

    BI 456906 TFA

    		 GLP Receptor GCGR Metabolic Disease
    Survodutide (BI 456906) TFA is a potent, selective glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist with EC50s of 0.52 nM and 0.33 nM in CHO-K1 cells, respectively. Survodutide TFA, a 29-amino-acid peptide, is a potent acylated peptide containing a C18 fatty acid. Survodutide TFA has robust anti-obesity efficacy achieved by increasing energy expenditure and decreasing food intake .
    Survodutide TFA
  • HY-173628
    (R,S,S)-VH032-Me-N-Boc-7-aminoheptanoic acid

    		E3 Ligase Ligand-Linker Conjugates Cancer
    (R,S,S)-VH032-Me-N-Boc-7-aminoheptanoic acid is a E3 Ligase Ligand-Linker Conjugate, consisting of N-Boc-7-aminoheptanoic acid (HY-W012001) and the corresponding Linker. (R,S,S)-VH032-Me-N-Boc-7-aminoheptanoic acid can be used for the synthesis of dTAGV-1-NEG (HY-145514A) .
    (R,S,S)-VH032-Me-N-Boc-7-aminoheptanoic acid
  • HY-173628A
    (S,R,S)-AHPC-Me-N-Boc-7-aminoheptanoic acid

    		E3 Ligase Ligand-Linker Conjugates Cancer
    (S,R,S)-AHPC-Me-N-Boc-7-aminoheptanoic acid is a conjugate of an E3 ligase ligand and a linker, which can be used for the synthesis of PROTAC dTAGV-1 TFA (HY-145514) .
    (S,R,S)-AHPC-Me-N-Boc-7-aminoheptanoic acid
  • HY-P10876
    mcK6A1

    		Amyloid-β Neurological Disease
    mcK6A1 is an inhibitor for the aggregation of amyloid-β (Aβ), that selectively binds to the 16KLVFFA21 segment of Aβ42, forms an extended β-folded structure, and inhibits the formation of Aβ42 oligomers. mcK6A1 can be used in research of Alzheimer's disease and other amyloid-related diseases .
    mcK6A1
  • HY-P10341
    ZP3022

    		GCGR Metabolic Disease
    ZP3022 is a dual agonist of glucagon-like peptide-1 (GLP-1) and gastrin that has the ability to sustainably improve glycemic control. Additionally, ZP3022 can effectively increase β-cell mass, promote β-cell proliferation, and enhance the function of pancreatic islets. ZP3022 can be used in anti-diabetic research .
    ZP3022

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: